REMASTer: REcurrent Brain Metastases After SRS Trial
Monteris Medical
Summary
Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Patients with radiographically proven (by gadolinium-enhanced \[Gd-\] MRI) parenchymal brain metastases from histologically confirmed non-central nervous system (CNS) cancer. 2. Patients with a "targetable", bidimensionally-measurable, intracranial lesion that is radiographically recurrent after previous treatment with SRS +/- surgery (craniotomy or LITT). To classify a lesion as radiographically progressive, the lesion must demonstrate a ≥ 25% increase in size…
Interventions
- ProcedureRadiation Therapy
Post-op hypofractionated therapy or no radiation therapy
- DrugSteroid Therapy
Best medical management with steroid therapy
- ProcedureLaser Interstitial Thermal Therapy
Minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
Locations (9)
- UCLALos Angeles, California
- University of ChicagoChicago, Illinois
- University of MarylandBaltimore, Maryland
- WashUSt Louis, Missouri
- Duke University HospitalDurham, North Carolina
- Wake Forest Baptist Medical CenterWinston-Salem, North Carolina